• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Genetics Market
Genetics News
Genetics Stocks
  • Genetics Market
  • Genetics News
  • Genetics Stocks

Cytori Therapeutics Announces Receipt of Puregraft Royalty Milestone

Gabrielle Lakusta
Oct. 30, 2018 08:38AM PST
Genetics Investing

Cytori Therapeutics (Nasdaq:CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies. The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft product line. As quoted in the press release: In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with …

Cytori Therapeutics (Nasdaq:CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies. The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft product line.

As quoted in the press release:

In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.

Bimini may also be obligated to make certain additional milestone payments to Cytori (in an aggregate amount of up to $10.0 million), contingent upon future achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products. The aggregate value of the consideration paid by Bimini to Cytori at the execution of the agreement in July 2013 was $5.0 million.

Click here to read the full press release.

cytori therapeutics nasdaq:cytx
The Conversation (0)

Go Deeper

AI Powered
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks (Updated January 2026)

Senior woman doing exercises alongside closeup of DNA.

5 US Longevity and Anti-aging Stocks to Watch

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES